Literature DB >> 21976060

CUEDC2: an emerging key player in inflammation and tumorigenesis.

Jianghong Man1, Xuemin Zhang.   

Abstract

CUE domain-containing 2 (CUEDC2) is a protein involved in the regulation of the cell cycle, inflammation, and tumorigenesis and is highly expressed in many types of tumors. CUEDC2 is phosphorylated by Cdk1 during mitosis and promotes the release of anaphase-promoting complex or cyclosome (APC/C) from checkpoint inhibition. CUEDC2 is also known to interact with IkB kinase α (IKKα) and IKKβ and has an inhibitory role in the activation of transcription factor nuclear factor-κB. Moreover, CUEDC2 plays an important role in downregulating the expression of hormone receptors estrogen receptor-α and progesterone receptor, thereby impairing the responsiveness of breast cancer to endocrine therapies. In this review, current knowledge on the multi-functions of CUEDC2 in normal processes and tumorigenesis are discussed and summarized.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21976060      PMCID: PMC4875262          DOI: 10.1007/s13238-011-1089-z

Source DB:  PubMed          Journal:  Protein Cell        ISSN: 1674-800X            Impact factor:   14.870


  42 in total

1.  A ubiquitin-binding motif required for intramolecular monoubiquitylation, the CUE domain.

Authors:  Susan C Shih; Gali Prag; Smitha A Francis; Myra A Sutanto; James H Hurley; Linda Hicke
Journal:  EMBO J       Date:  2003-03-17       Impact factor: 11.598

Review 2.  Regulation of the APC and the exit from mitosis.

Authors:  D O Morgan
Journal:  Nat Cell Biol       Date:  1999-06       Impact factor: 28.824

Review 3.  NF-kappaB: linking inflammation and immunity to cancer development and progression.

Authors:  Michael Karin; Florian R Greten
Journal:  Nat Rev Immunol       Date:  2005-10       Impact factor: 53.106

Review 4.  The extended PP1 toolkit: designed to create specificity.

Authors:  Mathieu Bollen; Wolfgang Peti; Michael J Ragusa; Monique Beullens
Journal:  Trends Biochem Sci       Date:  2010-05-01       Impact factor: 13.807

Review 5.  TNF-R1 signaling: a beautiful pathway.

Authors:  Guoqing Chen; David V Goeddel
Journal:  Science       Date:  2002-05-31       Impact factor: 47.728

6.  IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis.

Authors:  Shin Maeda; Hideaki Kamata; Jun-Li Luo; Hyam Leffert; Michael Karin
Journal:  Cell       Date:  2005-07-01       Impact factor: 41.582

7.  Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1.

Authors:  H Nakano; M Shindo; S Sakon; S Nishinaka; M Mihara; H Yagita; K Okumura
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

8.  Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3.

Authors:  Qiaojia Huang; Jianhua Yang; Yong Lin; Christopher Walker; Jinke Cheng; Zheng-gang Liu; Bing Su
Journal:  Nat Immunol       Date:  2003-12-07       Impact factor: 25.606

9.  Deactivation of the kinase IKK by CUEDC2 through recruitment of the phosphatase PP1.

Authors:  Hui-Yan Li; Hui Liu; Chen-Hui Wang; Ji-Yan Zhang; Jiang-Hong Man; Yan-Fei Gao; Pei-Jing Zhang; Wei-Hua Li; Jie Zhao; Xin Pan; Tao Zhou; Wei-Li Gong; Ai-Ling Li; Xue-Min Zhang
Journal:  Nat Immunol       Date:  2008-03-23       Impact factor: 25.606

10.  The aneuploidy paradox in cell growth and tumorigenesis.

Authors:  Beth A Weaver; Don W Cleveland
Journal:  Cancer Cell       Date:  2008-12-09       Impact factor: 31.743

View more
  7 in total

1.  CUE domain-containing protein 2 promotes the Warburg effect and tumorigenesis.

Authors:  Xiuying Zhong; Shengya Tian; Xiang Zhang; Xinwei Diao; Fangting Dong; Jie Yang; Zhaoyong Li; Linchong Sun; Lin Wang; Xiaoping He; Gongwei Wu; Xin Hu; Lihua Wang; Libing Song; Huafeng Zhang; Xin Pan; Ailing Li; Ping Gao
Journal:  EMBO Rep       Date:  2017-03-21       Impact factor: 8.807

2.  Suramin inhibits the development and progression of peritoneal fibrosis.

Authors:  Chongxiang Xiong; Na Liu; Lu Fang; Shougang Zhuang; Haidong Yan
Journal:  J Pharmacol Exp Ther       Date:  2014-08-28       Impact factor: 4.030

3.  Overexpression of CUEDC2 Predicts Poor Prognosis in Ovarian Serous Carcinomas.

Authors:  Aichun Wang; Chao Guo; Yunfei Sun; Lijuan Lu; Yun Wang; Qiong Wang; Yan Zhang; Hui Zhang; Li Wang; Yiqun Gu; Aijun Liu
Journal:  J Cancer       Date:  2015-04-29       Impact factor: 4.207

4.  CUEDC2 down-regulation is associated with tumor growth and poor prognosis in lung adenocarcinoma.

Authors:  Longhua Sun; Lihong Bai; Gengpeng Lin; Ran Wang; Yangli Liu; Jinghuang Cai; Yubiao Guo; Zhiwen Zhu; Canmao Xie
Journal:  Oncotarget       Date:  2015-08-21

5.  CUEDC2 suppresses glioma tumorigenicity by inhibiting the activation of STAT3 and NF-κB signaling pathway.

Authors:  Feng Li; Chuanxi Tang; Dan Jin; Li Guan; Yue Wu; Xinfeng Liu; Xiuxiang Wu; Qing Yun Wu; Dianshuai Gao
Journal:  Int J Oncol       Date:  2017-05-17       Impact factor: 5.650

6.  Downregulation of CUEDC2 prevents doxorubicin‑induced cardiotoxicity in H9c2 cells.

Authors:  Xianpu Zhang; Jiaojiao Li; Yongbo Cheng; Jianguang Yi; Xin Liu; Wei Cheng
Journal:  Mol Med Rep       Date:  2018-05-23       Impact factor: 2.952

7.  CUEDC1 inhibits epithelial-mesenchymal transition via the TβRI/Smad signaling pathway and suppresses tumor progression in non-small cell lung cancer.

Authors:  Yue Cui; Yang Song; Shi Yan; Mengru Cao; Jian Huang; Dexin Jia; Yuechao Liu; Shuai Zhang; Weina Fan; Li Cai; Chunhong Li; Ying Xing
Journal:  Aging (Albany NY)       Date:  2020-10-25       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.